ACQUIRED HEMOPHILIA A
Clinical trials for ACQUIRED HEMOPHILIA A explained in plain language.
Never miss a new study
Get alerted when new ACQUIRED HEMOPHILIA A trials appear
Sign up with your email to follow new studies for ACQUIRED HEMOPHILIA A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug watch: OBIZER injection under Real-World review for rare bleeding disorder
Disease control Recruiting nowThis study monitors 25 people in Japan with Acquired Hemophilia A who receive OBIZER (Susoctocog Alfa) injections to control bleeding. Researchers will track side effects and how well the drug stops bleeding for up to 90 days after the last dose. The goal is to confirm the drug's…
Matched conditions: ACQUIRED HEMOPHILIA A
Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 09:22 UTC
-
New study tracks safety of bleeding disorder drug OBIZUR
Disease control Recruiting nowThis study watches how safe OBIZUR is for adults with acquired hemophilia A, a rare condition that causes sudden and severe bleeding. About 9 people will be followed as they receive the drug in regular medical practice. The goal is to track side effects and see how well the drug …
Matched conditions: ACQUIRED HEMOPHILIA A
Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 09:21 UTC